1. Home
  2. ALNY vs HSY Comparison

ALNY vs HSY Comparison

Compare ALNY & HSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALNY
  • HSY
  • Stock Information
  • Founded
  • ALNY 2002
  • HSY 1894
  • Country
  • ALNY United States
  • HSY United States
  • Employees
  • ALNY N/A
  • HSY N/A
  • Industry
  • ALNY Biotechnology: Pharmaceutical Preparations
  • HSY Specialty Foods
  • Sector
  • ALNY Health Care
  • HSY Consumer Staples
  • Exchange
  • ALNY Nasdaq
  • HSY Nasdaq
  • Market Cap
  • ALNY 40.4B
  • HSY 32.7B
  • IPO Year
  • ALNY 2004
  • HSY N/A
  • Fundamental
  • Price
  • ALNY $320.87
  • HSY $162.80
  • Analyst Decision
  • ALNY Strong Buy
  • HSY Hold
  • Analyst Count
  • ALNY 24
  • HSY 20
  • Target Price
  • ALNY $341.91
  • HSY $164.05
  • AVG Volume (30 Days)
  • ALNY 863.4K
  • HSY 1.9M
  • Earning Date
  • ALNY 07-31-2025
  • HSY 07-30-2025
  • Dividend Yield
  • ALNY N/A
  • HSY 3.38%
  • EPS Growth
  • ALNY N/A
  • HSY N/A
  • EPS
  • ALNY N/A
  • HSY 8.12
  • Revenue
  • ALNY $2,348,099,000.00
  • HSY $10,754,933,000.00
  • Revenue This Year
  • ALNY $30.77
  • HSY $3.10
  • Revenue Next Year
  • ALNY $30.51
  • HSY $3.05
  • P/E Ratio
  • ALNY N/A
  • HSY $19.95
  • Revenue Growth
  • ALNY 17.21
  • HSY N/A
  • 52 Week Low
  • ALNY $205.87
  • HSY $140.13
  • 52 Week High
  • ALNY $333.70
  • HSY $208.03
  • Technical
  • Relative Strength Index (RSI)
  • ALNY 57.52
  • HSY 46.37
  • Support Level
  • ALNY $314.10
  • HSY $164.80
  • Resistance Level
  • ALNY $328.99
  • HSY $178.06
  • Average True Range (ATR)
  • ALNY 9.40
  • HSY 3.85
  • MACD
  • ALNY -1.23
  • HSY -0.30
  • Stochastic Oscillator
  • ALNY 52.48
  • HSY 13.95

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

About HSY The Hershey Company

Hershey is a leading US confectionery manufacturer (around a $54 billion market, according to Euromonitor), controlling around 36% of the domestic chocolate space. Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the US, including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix, Pirate Brands, and Dot's Pretzels over the past few years.

Share on Social Networks: